Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Bolt Biotherapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 62 | 56 | −6 |
| Shares | 26.8M | 26.8M | −39.0K (−0.1%) |
| Value | $54.8M | $39.7M | −$15.1M (−27.6%) |
New holders (7)
Institutions that held Bolt Biotherapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| OrbiMed Advisors LLC | 771,059 | $1.14M | 0.02% |
| Caas Capital Management LP | 116,777 | $173.0K | 0.02% |
| Privium Fund Management (UK) Ltd | 116,516 | $172.0K | 0.22% |
| Bailard, Inc. | 46,383 | $69.0K | 0.00% |
| Dimensional Fund Advisors LP | 10,071 | $15.0K | 0.00% |
| Federated Hermes, Inc. | 2,143 | $3.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 353 | $1.00K | 0.00% |
Sold out (13)
Institutions that held Bolt Biotherapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| EcoR1 Capital, LLC | 150,000 | $306.0K |
| D. E. Shaw & Co., Inc. | 36,426 | $74.0K |
| Two Sigma Investments, LP | 34,754 | $71.0K |
| HRT Financial LP | 34,751 | $70.0K |
| Two Sigma Advisers, LP | 26,300 | $54.0K |
| Susquehanna International Group, LLP | 17,535 | $36.0K |
| Prelude Capital Management, LLC | 10,994 | $22.0K |
| UBS Group AG | 2,511 | $5.00K |
| Legal & General Group Plc | 1,833 | $4.00K |
| Royal Bank of Canada | 1,000 | $2.00K |
| New York State Common Retirement Fund | 188 | $0 |
| Credit Suisse AG | 12 | $0 |
| Capital Advisors, Ltd. LLC | 106 | $0 |